JA Ledermann
- Reproductive Medicine top 2%
- Ovarian cancer diagnosis and treatment 23
- Oncology top 5%
- PARP inhibition in cancer therapy 10
- Colorectal Cancer Treatments and Studies 6
- Surgery top 5%
- Colorectal and Anal Carcinomas 7
-
- Monoclonal and Polyclonal Antibodies Research 10
- Radiopharmaceutical Chemistry and Applications 8
-
- BRCA gene mutations in cancer 7
-
- Neuroendocrine Tumor Research Advances 6
- Co-authors
- David Sebag‐MontefioreHelen MeadowsRob Glynne‐JonesJohn NorthoverR.D. JamesSusan WanMark JitlalRebecca Kristeleit
- Cited by
- Reproductive MedicineOncologySurgery
- Journals
- British Journal of Cancer (12 papers)Annals of Oncology (12 papers)European Journal of Cancer (5 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
JA Ledermann
67 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 96
- Reproductive Medicine 407
- Oncology 904
- Surgery 764
- Radiology, Nuclear Medicine and Imaging 311
- Pulmonary and Respiratory Medicine 439
Countries citing papers authored by JA Ledermann
This map shows the geographic impact of JA Ledermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JA Ledermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JA Ledermann more than expected).
Fields of papers citing papers by JA Ledermann
This network shows the impact of papers produced by JA Ledermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JA Ledermann. The network helps show where JA Ledermann may publish in the future.
Co-authorship network
The 25 scholars most cited alongside JA Ledermann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2020 | 16 | |
| 3 | 2019 | 0 | |
| 4 | 2017 | 4 | |
| 5 | 2016 | 7 | |
| 6 | 2014 | 64 | |
| 7 | Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial | 2013 | 75 |
| 8 | ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC) | 2010 | 34 |
| 9 | 2010 | 63 | |
| 10 | 2007 | 2 | |
| 11 | 2004 | 156 | |
| 12 | Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial (vol 361, pg 2099, 2003) | 2003 | 2 |
| 13 | Clinical management of ovarian cancer | 2001 | 3 |
| 14 | Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06 | 2000 | 17 |
| 15 | Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer | 1999 | 41 |
| 16 | 1998 | 6 | |
| 17 | 1997 | 58 | |
| 18 | 1994 | 10 | |
| 19 | 1993 | 8 | |
| 20 | PHASE I/II STUDY OF CHIMERIC B72.3 ANTIBODY IN RADIOIMMUNOTHERAPY OF COLORECTAL-CARCINOMA | 1990 | 7 |
About JA Ledermann
JA Ledermann is a scholar working on Reproductive Medicine, Oncology and Hepatology, having authored 69 papers that have together received 2.0k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (23 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), PARP inhibition in cancer therapy (10 papers), Radiopharmaceutical Chemistry and Applications (8 papers), BRCA gene mutations in cancer (7 papers), Colorectal and Anal Carcinomas (7 papers), Neuroendocrine Tumor Research Advances (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). The work is most often cited by research in Reproductive Medicine (407 citations), Oncology (904 citations) and Surgery (764 citations). JA Ledermann has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include David Sebag‐Montefiore, Helen Meadows, Rob Glynne‐Jones, John Northover, R.D. James, Susan Wan, Mark Jitlal, Rebecca Kristeleit, N. J. Mortensen and Nicholas Counsell. Their work appears in journals such as British Journal of Cancer, Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology and International Journal of Gynecological Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.